ANIXA BIOSCIENCES
Anixa is a publicly-traded biotechnology company focused on harnessing the body's immune system in the fight against cancer. Anixa's therapeutic portfolio includes a cancer vaccine technology focused on the immunization against ฮฑ-Lactalbumin to prevent triple negative breast cancer (TNBC), as well as a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology. The company's diagnostic portfolio consists of Cchekโข, a liquid biopsy technology for early detection of solid tumors based on the body's immune response to the presence of a malignancy. Anixa continually examines emerging technologies in complementary fields for further development and commercialization.
ANIXA BIOSCIENCES
Industry:
Biotechnology Finance Market Research Pharmaceutical Therapeutics
Founded:
1982-01-01
Address:
Melville, New York, United States
Country:
United States
Website Url:
http://www.anixa.com
Total Employee:
1+
Status:
Active
Contact:
6315495974
Total Funding:
34.27 M USD
Technology used in webpage:
U.S. Server Location
Similar Organizations
Aclaris Therapeutics
Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focusesย on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Inovio Pharmaceuticals
Inovio is a biotech company focusing on bringing to market DNA medicines for diseases associated with HPV, cancer, and infectious diseases.
PBS-Bio
PBS-Bio develops cancer treatment technologies for pre-clinical research to pharmaceutical clients.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
U.S. Department of Defense
U.S. Department of Defense investment in Grant - Anixa Biosciences
National Cancer Institute
National Cancer Institute investment in Grant - Anixa Biosciences
Key Employee Changes
Official Site Inspections
http://www.anixa.com Semrush global rank: 7.99 M Semrush visits lastest month: 666
- Host name: ec2-54-208-101-55.compute-1.amazonaws.com
- IP address: 54.208.101.55
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Anixa Biosciences"
Overview - Anixa Biosciences, Inc. (ANIX)
Anixa's therapeutics portfolio consists of a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology. Anixaโs vaccine portfolio consists of technology focused on the immunization against specific โretiredโ proteins associated with breast cancer, specifically triple negative breast cancer (TNBC), and ovarian โฆSee details»
Anixa Biosciences - Crunchbase Company Profile & Funding
Anixa is a publicly-traded biotechnology company focused on harnessing the body's immune system in the fight against cancer. Anixa's therapeutic portfolio includes a cancer vaccine technology focused on the immunization against ฮฑ-Lactalbumin to prevent triple negative breast cancer (TNBC), as well as a cancer immunotherapy program whichSee details»
Anixa Biosciences, Inc. (ANIX) - Yahoo Finance Canada
See the company profile for Anixa Biosciences, Inc. (ANIX) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives and their compensation.See details»
Anixa Biosciences, Inc. (ANIX) - Yahoo Finance
See the company profile for Anixa Biosciences, Inc. (ANIX) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives and ...See details»
Anixa Biosciences 2025 Annual Meeting of Stockholders to Include ...
SAN JOSE, Calif., March 10, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today ...See details»
Anixa Biosciences, Inc. (ANIX) - Yahoo Finance
Find the latest Anixa Biosciences, Inc. (ANIX) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
Press Releases :: Anixa Biosciences, Inc. (ANIX)
SAN JOSE, Calif., March 2, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that its CEO, Dr. Amit Kumar, will provide a corporate presentation on the company, its business model, and updates on each of its programs and will host a โฆSee details»
Anixa Biosciences Inc - Company Profile - GlobalData
Anixa Biosciences company overview and more information Anixa Biosciences Inc (Anixa) is a biotechnology company. The company develops and acquires patented technologies in the areas such as cancer diagnostics, encrypted communications and semiconductor fabrication. It also develops non-invasive blood tests for the early detection of solid ...See details»
Press Releases :: Anixa Biosciences, Inc. (ANIX)
SAN JOSE, Calif., Feb. 24, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today is pleased to announce that its pioneering CAR-T therapy for ovarian cancer, developed in collaboration with Moffitt Cancer Center ("Moffitt"), was prominently โฆSee details»
Introduction :: Anixa Biosciences, Inc. (ANIX)
Anixa believes that one of the primary reasons that CAR-T efficacy in solid tumors has been elusive is due to the lack of known antigens on the surface of solid tumor cells. To understand this key attribute, it is useful to review key characteristics of the liquid tumor successes.See details»
Anixa Biosciences to Present at the 18th Annual European Life โฆ
Feb 11, 2025 Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Mike Catelani, President and CFO ...See details»
Anixa Biosciences' Chairman & CEO Dr. Amit Kumar Featured on โฆ
Feb 4, 2025 Anixa's business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields ...See details»
Press Releases :: Anixa Biosciences, Inc. (ANIX)
Apr 19, 2021 About Anixa Biosciences, Inc. Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease. Anixa's therapeutics portfolio includes a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a Covid-19 therapeutics program โฆSee details»
Markets :: Anixa Biosciences, Inc. (ANIX)
Anixa Biosciences CEO to Present at the 2025 CAGLA NeauxCancer Conference on March 28th. Read More... Mar 10, 2025. Anixa Biosciences 2025 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties. Read More... Mar 3, 2025.See details»
Maxim Group Initiates Coverage of Anixa Biosciences (ANIX
4 days ago There are 75 funds or institutions reporting positions in Anixa Biosciences. This is an increase of 1 owner(s) or 1.35% in the last quarter. This is an increase of 1 owner(s) or 1.35% in the last ...See details»
Anixa Biosciences announces approval of protocol amendment for โฆ
Feb 18, 2025 Anixa Biosciences announced that it, along with its partner Moffitt Cancer Center, has received approval for an amendment to the protocol governing its ongoing clinical trial using CAR-T therapy ...See details»
Press Releases :: Anixa Biosciences, Inc. (ANIX)
About Anixa Biosciences, Inc. Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease. Anixa's therapeutics portfolio includes a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a Covid-19 therapeutics program focused โฆSee details»
Press Releases :: Anixa Biosciences, Inc. (ANIX)
Nov 8, 2022 Anixa is a clinical-stage biotechnology company with programs addressing cancer and infectious disease. Anixa's portfolio of therapeutics includes a cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and, with partner โฆSee details»
Science :: Anixa Biosciences, Inc. (ANIX)
Anixa Biosciences CEO to Present at the 2025 CAGLA NeauxCancer Conference on March 28th. Read More... Mar 10, 2025. Anixa Biosciences 2025 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties. Read More... Mar 3, 2025.See details»
In Brief This Week: ReCode, Anixa Biosciences, U of Cologne, Eisai ...
Nov 22, 2024 Anixa Biosciences this week said it dosed the first patient of a third cohort of study participants in a Phase I trial of its FSHR-mediated CAR T-cell therapy for recurrent ovarian cancer who have progressed on at least two prior therapies. Patients in this cohort will receive a dose 10 times higher than the starting dose.See details»